Clinical efficacy of tislelizumab combined with conventional chemotherapeutic agents in patients with advanced non-small cell lung cancer and its influence on serum tumor markers
Objective To explore the clinical efficacy of tislelizumab combined with conventional chemotherapeutic agents in patients with advanced non-small cell lung cancer and its influence on serum tumor markers.Methods 80 patients with advanced non-small cell lung cancer were retrospectively selected,of which 40 patients receiving gemcitabine monotherapy were included as the control group and 40 patients receiving gemcitabine combined with tislelizumab as the observation group.Observation and comparison were made on clinical efficacy,serum tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)]levels,36-item short-form health survey(SF-36)score before and after treatment,and incidence of adverse drug reactions between the two groups.Results Compared with the control group(70.0% ),the disease remission rate of the observation group(90.0% )was significantly higher(P<0.05).Compared with before treatment,SF-36 scores in both groups were significantly improved after 3 courses of treatment(P<0.05).Compared with the control group[(63.28±4.63)points],SF-36 score of the observation group[(86.34±5.32)points]was significantly higher(P<0.05).Before treatment,there were no differences in serum CA125,CEA and NSE levels between the two groups(P>0.05).Compared with before treatment,the serum CA125,CEA and NSE levels in both groups were decreased after 3 courses of treatment(P<0.05).After 3 courses of treatment,the serum levels of CA125,CEA and NSE in the observation group were(32.92±2.38)U/ml,(16.85±2.23)ng/ml and(6.54±1.67)ng/ml,which were significantly lower than(63.32±2.31)U/ml,(29.27±2.29)ng/ml and(22.15±1.88)ng/ml in the control group(P<0.05).There was no difference in the incidence of adverse drug reactions between the control group(7.5% )and the observation group(5.0% )(P>0.05).Conclusion After the combination treatment of tislelizumab and conventional chemotherapeutic agents,the clinical symptoms of patients with advanced non-small cell lung cancer are significantly improved,and the clinical efficacy is significantly enhanced.It can effectively reduce the serum levels of tumor markers,improve the quality of life of patients,and has good safety,which is worthy of clinical promotion.
万方数据
维普
